South Korea's Celltrion unveiled positive results from its pre-clinical study for a novel COVID-19 antiviral treatment, reporting that the antibody treatment tested in animals reduced viral load by a hundredfold in those given the high dose, while lung inflammation in both high- and low-dosage cohort cleared within six days, with the drug also shortening recovery time. Plans are in place to launch the first in-human clinical trials in July.
Celltrion reports positive data from COVID-19 antiviral drug
Sign up for BIO SmartBrief
Biotechnology industry news
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.